Q2 FY26 PAT rises 35 percent to Rs 689 crore
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty 100 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Divi's Laboratories reported unaudited consolidated Q2 FY26 revenue from operations of Rs 2,715 crore and total income of Rs 2,860 crore. PAT rose 35 percent year on year to Rs 689 crore, and PBT rose to Rs 912 crore. H1 FY26 PAT was Rs 1,234 crore, up 31 percent. Operating cash inflow reached Rs 1,645 crore. Forex gain was Rs 63 crore versus Rs 29 crore a year earlier, and the auditor's limited review was unmodified.
Strong profit growth and cash generation help shareholders, but higher forex gains may not repeat and could make earnings volatile.